Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00811746 · ClinicalTrials.gov registry record · NA

Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?

A NA study of Obstructive Sleep Apnea, sponsored by Southern California Institute for Research and Education.

Completed
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT00811746 is a NA study of Obstructive Sleep Apnea that has completed, run by Southern California Institute for Research and Education. The registered enrollment target is 90 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00811746, a NA study of Obstructive Sleep Apnea, has completed, sponsored by Southern California Institute for Research and Education.

COMPLETED
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted to determine if eszopiclone is as effective as ramelteon when used as a pre-medication (sleeping pill) in sleep studies performed to diagnose and treat sleep apnea.

Conditions Studied

Interventions

  • DRUG Rozerem (Ramelteon)
  • DRUG Lunesta (Eszopiclone)
  • OTHER Historical Controls

Study Locations (1)

California

  • VA Long Beach Healthcare System - Long Beach

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2008-12
Est. Completion 2010-10
Phase NA

What the Registry Record Tells You About NCT00811746

The ClinicalTrials.gov registry entry for NCT00811746 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (59% lower). The listed sponsor is Southern California Institute for Research and Education, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 3 interventions - of which Rozerem (Ramelteon) is the first listed.

NCT00811746 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00811746 about?

NCT00811746 is a clinical study titled "Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?". This study is being conducted to determine if eszopiclone is as effective as ramelteon when used as a pre-medication (sleeping pill) in sleep studies performed to diagnose and treat sleep apnea.

What is the current status of trial NCT00811746?

This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2008-12. Estimated completion is 2010-10.

What conditions does trial NCT00811746 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea.

What interventions are being tested in trial NCT00811746?

The interventions under investigation include: Rozerem (Ramelteon) (DRUG), Lunesta (Eszopiclone) (DRUG), Historical Controls (OTHER).

Who is sponsoring clinical trial NCT00811746?

This trial is sponsored by Southern California Institute for Research and Education, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00811746 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.